use of il-17 antagonists to inhibit progression of structural damage in psoriatic arthritis patients

摘要

The present invention relates to methods, uses, medicaments, pharmaceutical formulations, dosage forms and kits for inhibiting the progression of structural damage in psoriatic arthritis (psa) patients using il-17 antagonists, for example antibodies. of il-17 and antigen binding fragments thereof, for example, secuquinumab.